Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

the EUMDS Registry Participants

doi:10.1038/s41375-020-01022-2

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

the EUMDS Registry Participants

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Original language	English
Pages (from-to)	1745-1750
Number of pages	6
Journal	Leukemia
Volume	35
Issue number	6
DOIs	https://doi.org/10.1038/s41375-020-01022-2
Publication status	Published - Jun 2021
Externally published	Yes

Access to Document

10.1038/s41375-020-01022-2Licence: CC BY

Cite this

@article{07fbe47faaba4042b8d8e907e1f9c2d6,

title = "Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome",

author = "{the EUMDS Registry Participants} and Marlijn Hoeks and Tim Bagguley and {van Marrewijk}, Corine and Alex Smith and David Bowen and Dominic Culligan and Seye Kolade and Argiris Symeonidis and Hege Garelius and Michail Spanoudakis and Saskia Langemeijer and Rian Roelofs and Erwin Wiegerinck and Aurelia Tatic and Sally Killick and Panagiotis Panagiotidis and Oana Stanca and Eva Hellstr{\"o}m-Lindberg and Jaroslav Cermak and {van der Klauw}, Melanie and Hanneke Wouters and {van Kraaij}, Marian and Nicole Blijlevens and Swinkels, {Dorine W.} and {de Witte}, Theo and R. Stauder and A. Walder and M. Pfeilst{\"o}cker and A. Schoenmetzler-Makrai and S. Burgstaller and J. Thaler and {Mandac Rogulj}, I. and M. Krejci and J. Voglova and P. Rohon and A. Jonasova and J. Cermak and D. Mikulenkova and I. Hochova and Jensen, {P. D.} and Holm, {M. S.} and L. Kjeldsen and Dufva, {I. H.} and H. Vestergaard and D. Re and B. Slama and P. Fenaux and B. Choufi and S. Cheze and A. Almeida",

note = "Funding Information: Infirmary, Aberdeen, UK; 148Queen Elizabeth Hospital, Birmingham, UK; 149Blackpool Victoria Hospital, Blackpool, UK; 150Royal Bournemouth Hospital, Bournemouth, UK; 151Bradford Royal Infirmary, Bradford, UK; 152Addenbrooke{\textquoteright}s Hospital, Cambridge, UK; 153Western Infirmary, Glasgow, UK; 154Harrogate District Hospital, Harrogate, UK; 155Huddersfield Royal Infirmary, Huddersfield, UK; 156Hull and East Yorkshire Hospitals NHS Trust, Hull, UK; 157Leeds Teaching Hospitals, Leeds, UK; 158Christie Hospital, Manchester, UK; 159Royal Victoria Infirmary, Newcastle upon Tyne, UK; 160Northampton General Hospital, Northampton, UK; 161City Hospital, Nottingham, UK; 162John Radcliffe Hospitals NHS Trust, Oxford, UK; 163Airedale NHS Trust, Steeton, UK; 164Royal Cornwall Hospital, Truro, UK; 165Mid Yorkshire Hospitals, Wakefield, UK; 166Worcestershire Acute Hospitals NHS Trust, Worcester, UK; 167York Hospital, York, UK Funding The EUMDS Registry is supported by an educational grant from Novartis Pharmacy B.V. Oncology Europe, and Amgen Limited. This work is part of the MDS-RIGHT activities, which has received funding from the European Union{\textquoteright}s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 634789 MDS-RIGHT—“Providing the right care to the right patient with Myelo-Dysplastic Syndrome at the right time.” The Lifelines Biobank initiative has been made possible by subsidy from the Dutch Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University Medical Center Groningen (UMCG the Netherlands), University Groningen, and the Northern Provinces of the Netherlands. The authors wish to acknowledge the services of the Lifelines Cohort Study, the contributing research centers delivering data to Lifelines, and all the study participants. Funding Information: Conflict of interest CvM: project manager of the EUMDS Registry, is funded by the EUMDS and MDS-RIGHT project budget; ASm: research funding from Novartis, Cilag-Janssen, and Boehringer Ingelheim; ASy: honoraria and consulting fees from Amgen, Celgene/ GenesisPharma, Genzyme/Sanofi, Gilead, Janssen-Cilag, Pfizer, MSD, and Novartis; HG: honoraria from Celgene, Novartis, and Alexion; SK: honoraria from Novartis, Jazz, and Celgene; EH-L: research funding from Celgene; NB: research funding from Novartis, Bristol Meyer Squibb, Pfizer, Ariad, MSD, Astellas, Xenikos, and Celgene, educational grant from Novartis, Celgene, and Janssen-Cilag; DWS: paid employee of RadboudUMC, which offers hepcidin measurements via Hepcidinanalysis.com at a fee for service basis; TdW: research funding from Amgen, Celgene, and Novartis, as project coordinator EUMDS. The other authors declare that they have no conflict of interest.",

year = "2021",

month = jun,

doi = "10.1038/s41375-020-01022-2",

language = "English",

volume = "35",

pages = "1745--1750",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "6",

}

TY - JOUR

T1 - Toxic iron species in lower-risk myelodysplastic syndrome patients

T2 - course of disease and effects on outcome

AU - the EUMDS Registry Participants

AU - Hoeks, Marlijn

AU - Bagguley, Tim

AU - van Marrewijk, Corine

AU - Smith, Alex

AU - Bowen, David

AU - Culligan, Dominic

AU - Kolade, Seye

AU - Symeonidis, Argiris

AU - Garelius, Hege

AU - Spanoudakis, Michail

AU - Langemeijer, Saskia

AU - Roelofs, Rian

AU - Wiegerinck, Erwin

AU - Tatic, Aurelia

AU - Killick, Sally

AU - Panagiotidis, Panagiotis

AU - Stanca, Oana

AU - Hellström-Lindberg, Eva

AU - Cermak, Jaroslav

AU - van der Klauw, Melanie

AU - Wouters, Hanneke

AU - van Kraaij, Marian

AU - Blijlevens, Nicole

AU - Swinkels, Dorine W.

AU - de Witte, Theo

AU - Stauder, R.

AU - Walder, A.

AU - Pfeilstöcker, M.

AU - Schoenmetzler-Makrai, A.

AU - Burgstaller, S.

AU - Thaler, J.

AU - Mandac Rogulj, I.

AU - Krejci, M.

AU - Voglova, J.

AU - Rohon, P.

AU - Jonasova, A.

AU - Cermak, J.

AU - Mikulenkova, D.

AU - Hochova, I.

AU - Jensen, P. D.

AU - Holm, M. S.

AU - Kjeldsen, L.

AU - Dufva, I. H.

AU - Vestergaard, H.

AU - Re, D.

AU - Slama, B.

AU - Fenaux, P.

AU - Choufi, B.

AU - Cheze, S.

AU - Almeida, A.

N1 - Funding Information: Infirmary, Aberdeen, UK; 148Queen Elizabeth Hospital, Birmingham, UK; 149Blackpool Victoria Hospital, Blackpool, UK; 150Royal Bournemouth Hospital, Bournemouth, UK; 151Bradford Royal Infirmary, Bradford, UK; 152Addenbrooke’s Hospital, Cambridge, UK; 153Western Infirmary, Glasgow, UK; 154Harrogate District Hospital, Harrogate, UK; 155Huddersfield Royal Infirmary, Huddersfield, UK; 156Hull and East Yorkshire Hospitals NHS Trust, Hull, UK; 157Leeds Teaching Hospitals, Leeds, UK; 158Christie Hospital, Manchester, UK; 159Royal Victoria Infirmary, Newcastle upon Tyne, UK; 160Northampton General Hospital, Northampton, UK; 161City Hospital, Nottingham, UK; 162John Radcliffe Hospitals NHS Trust, Oxford, UK; 163Airedale NHS Trust, Steeton, UK; 164Royal Cornwall Hospital, Truro, UK; 165Mid Yorkshire Hospitals, Wakefield, UK; 166Worcestershire Acute Hospitals NHS Trust, Worcester, UK; 167York Hospital, York, UK Funding The EUMDS Registry is supported by an educational grant from Novartis Pharmacy B.V. Oncology Europe, and Amgen Limited. This work is part of the MDS-RIGHT activities, which has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 634789 MDS-RIGHT—“Providing the right care to the right patient with Myelo-Dysplastic Syndrome at the right time.” The Lifelines Biobank initiative has been made possible by subsidy from the Dutch Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University Medical Center Groningen (UMCG the Netherlands), University Groningen, and the Northern Provinces of the Netherlands. The authors wish to acknowledge the services of the Lifelines Cohort Study, the contributing research centers delivering data to Lifelines, and all the study participants. Funding Information: Conflict of interest CvM: project manager of the EUMDS Registry, is funded by the EUMDS and MDS-RIGHT project budget; ASm: research funding from Novartis, Cilag-Janssen, and Boehringer Ingelheim; ASy: honoraria and consulting fees from Amgen, Celgene/ GenesisPharma, Genzyme/Sanofi, Gilead, Janssen-Cilag, Pfizer, MSD, and Novartis; HG: honoraria from Celgene, Novartis, and Alexion; SK: honoraria from Novartis, Jazz, and Celgene; EH-L: research funding from Celgene; NB: research funding from Novartis, Bristol Meyer Squibb, Pfizer, Ariad, MSD, Astellas, Xenikos, and Celgene, educational grant from Novartis, Celgene, and Janssen-Cilag; DWS: paid employee of RadboudUMC, which offers hepcidin measurements via Hepcidinanalysis.com at a fee for service basis; TdW: research funding from Amgen, Celgene, and Novartis, as project coordinator EUMDS. The other authors declare that they have no conflict of interest.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85091002113&partnerID=8YFLogxK

U2 - 10.1038/s41375-020-01022-2

DO - 10.1038/s41375-020-01022-2

M3 - Article

C2 - 32948844

AN - SCOPUS:85091002113

SN - 0887-6924

VL - 35

SP - 1745

EP - 1750

JO - Leukemia

JF - Leukemia

IS - 6

ER -

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Access to Document

Other files and links

Cite this